TAIWAN LIPOSOME/S (NASDAQ:TLC) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Earnings & Valuation
This table compares TAIWAN LIPOSOME/S and Ultragenyx Pharmaceutical’s top-line revenue, earnings per share and valuation.
TAIWAN LIPOSOME/S has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.
This is a breakdown of recent recommendations and price targets for TAIWAN LIPOSOME/S and Ultragenyx Pharmaceutical, as reported by MarketBeat.
TAIWAN LIPOSOME/S currently has a consensus target price of $10.33, indicating a potential upside of 47.62%. Ultragenyx Pharmaceutical has a consensus target price of $75.31, indicating a potential upside of 52.05%. Given Ultragenyx Pharmaceutical’s higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than TAIWAN LIPOSOME/S.
This table compares TAIWAN LIPOSOME/S and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.
Insider & Institutional Ownership
97.6% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 8.4% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ultragenyx Pharmaceutical beats TAIWAN LIPOSOME/S on 6 of the 11 factors compared between the two stocks.
About TAIWAN LIPOSOME/S
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, is an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) that is in Phase II clinical trials for knee osteoarthritis pain. The company's product candidates also comprises TLC399, BioSeizer formulation of DSP intended as an intravitreal injection for the treatment of macular edema due to retinal vein occlusion; TLC590, a non-opioid anesthetic for post-surgical pain management; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.